CagriSema FDA decision — what changes if it is approved?
CagriSema is an investigational drug combination from Novo Nordisk. It is not FDA-approved, it is not available by prescription, and any site offering to sell it today is not offering a legal, approved product.
An FDA decision is expected in late 2026. If CagriSema is approved, it would enter the same coverage process as Wegovy and Zepbound, with most plans deciding coverage in later plan updates. Until then, the options that exist today are the ones on this site: check your current coverage, appeal a denial, or compare cash-pay prices. Compounded drugs are not FDA-approved.
Check your coverageYour options ladder
Step 1
Compare telehealth programs
Compare the ongoing total, membership fees, billing period and services included. A licensed healthcare professional decides whether a prescription is appropriate.
Step 2
Review compounded options
NuvoTrim’s price table lists compounded options from $99 per month. Compounded drugs are not FDA-approved.
Compare cash-pay programs
Partner
Compounded drugs are not FDA-approved.
Partner link. NuvoTrim may earn a fee if you sign up, at no extra cost to you.
Semaglutide from $99/mo · Tirzepatide from $129/mo
Eden: Compounded semaglutide and compounded tirzepatide, by prescription after an online clinician review.
Monthly subscription, no long-term plan required; labwork included when needed.
Check eligibilityHealthRX: Compounded semaglutide and compounded tirzepatide, by prescription after an online clinician review.
3-month plans.
Check eligibilitySemaglutide $199/mo · Tirzepatide $249/mo
Belle: Compounded semaglutide and compounded tirzepatide, by prescription after an online clinician review.
No membership fee; dietitian access included.
Check eligibilityFind out if your plan drops GLP-1s
Many plans renew January 1. Know the date your coverage changes and what staying on your medicine costs. We email you when we log a dated change, with its source.
By signing up, you agree to get NuvoTrim coverage alerts and a weekly update by email from Reta Watch, run by PeptideX (the team behind nuvotrim.com and startreta.com). Free. Unsubscribe anytime. We never sell your email. Education only, not medical advice. Not affiliated with any drugmaker, insurer or government program.
